-
261
Targeting HER2 expression in cancer: New drugs and new indications
Published 2021-02-01Get full text
Article -
262
New and emerging targeted systemic therapies: a new era for atopic dermatitis
Published 2018-05-01Get full text
Article -
263
-
264
The Role of Glutathione in the Management of Cell-Mediated Immune Responses in Individuals with HIV
Published 2024-03-01Get full text
Article -
265
Teneurin trans-axonal signaling prunes topographically missorted axons
Published 2023-03-01Get full text
Article -
266
An Innovative Comparative Analysis Approach for the Assessment of Laparoscopic Surgical Skills
Published 2023-02-01Get full text
Article -
267
-
268
-
269
-
270
Diffuse B-cell lymphoma of the mandible disguised as acute osteomyelitis
Published 2024-01-01Get full text
Article -
271
Beyond Cellular Immunity: On the Biological Significance of Insect Hemocytes
Published 2023-02-01Get full text
Article -
272
-
273
-
274
-
275
Stem Cell Therapy for Microvascular Injury Associated with Ischemic Nephropathy
Published 2021-03-01Get full text
Article -
276
-
277
-
278
Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
Published 2023-02-01“…Shane Root,1– 3 Kevin Ahn,3 Jack Kirsch,3 Justin L Hoskin1– 3 1Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA; 2University of Arizona School of Medicine, Phoenix, AZ, USA; 3Creighton University School of Medicine, Omaha, NE, USACorrespondence: Shane Root, Department of Neurology, Barrow Neurological Institute, 240 West Thomas Road Suite 400, Phoenix, AZ, 85013, USA, Tel +1 602 406 6262, Email shane.root@commonspirit.orgAbstract: Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) were the first class of medication specifically developed for the prevention of migraine. …”
Get full text
Article -
279
-
280